Naveen L Pereira

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation
    Naveen L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Circ Cardiovasc Genet 6:201-10. 2013
  2. pmc The impact of pharmacogenomics on the management of cardiac disease
    N L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 90:493-5. 2011
  3. pmc Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation
    Naveen L Pereira
    Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Mol Cell Cardiol 49:864-74. 2010
  4. pmc Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices
    Naveen L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Interact Cardiovasc Thorac Surg 11:503-5. 2010
  5. pmc Cardiovascular pharmacogenomics and individualized drug therapy
    Naveen L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Cardiol 6:632-8. 2009
  6. doi request reprint De novo development of eosinophilic myocarditis with left ventricular assist device support as bridge to transplant
    Naveen L Pereira
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 90:1345-7. 2010
  7. pmc Usefulness of the six-minute walk test after continuous axial flow left ventricular device implantation to predict survival
    Tal Hasin
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Am J Cardiol 110:1322-8. 2012
  8. doi request reprint Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation
    Yan Topilsky
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Circulation 125:708-20. 2012
  9. pmc Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study
    Yan Topilsky
    Division of Cardiovascular Diseases and Internal Medicine, Mayo College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Transplantation 95:389-96. 2013
  10. doi request reprint Changes in renal function after implantation of continuous-flow left ventricular assist devices
    Tal Hasin
    Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Am Coll Cardiol 59:26-36. 2012

Collaborators

Detail Information

Publications35

  1. pmc Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation
    Naveen L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Circ Cardiovasc Genet 6:201-10. 2013
    ..This genetic variation could have a significant effect on the metabolism of natriuretic peptides with potential clinical implications...
  2. pmc The impact of pharmacogenomics on the management of cardiac disease
    N L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 90:493-5. 2011
    ..However, many barriers need to be overcome for cardiovascular pharmacogenomics to have its promised clinical impact...
  3. pmc Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation
    Naveen L Pereira
    Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Mol Cell Cardiol 49:864-74. 2010
    ..This polymorphism could have a significant effect on the metabolism of natriuretic peptides...
  4. pmc Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices
    Naveen L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Interact Cardiovasc Thorac Surg 11:503-5. 2010
    ..Clinical trials are required to address the question whether it is safe to discontinue anticoagulation in LVAD patients with acquired VWF abnormalities...
  5. pmc Cardiovascular pharmacogenomics and individualized drug therapy
    Naveen L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Cardiol 6:632-8. 2009
    ..This article reviews the development, promise and challenges facing pharmacogenomics, using examples of drugs used to treat or prevent cardiovascular disease...
  6. doi request reprint De novo development of eosinophilic myocarditis with left ventricular assist device support as bridge to transplant
    Naveen L Pereira
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 90:1345-7. 2010
    ..There may be no visible change in cardiac function as assessed by echocardiography, but the diagnosis should be entertained with the development of peripheral eosinophilia...
  7. pmc Usefulness of the six-minute walk test after continuous axial flow left ventricular device implantation to predict survival
    Tal Hasin
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Am J Cardiol 110:1322-8. 2012
    ....
  8. doi request reprint Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation
    Yan Topilsky
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Circulation 125:708-20. 2012
    ..We retrospectively analyzed the potential of sirolimus as a primary immunosuppressant in the long-term attenuation of cardiac allograft vasculopathy progression and the effects on cardiac-related morbidity and mortality...
  9. pmc Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study
    Yan Topilsky
    Division of Cardiovascular Diseases and Internal Medicine, Mayo College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Transplantation 95:389-96. 2013
    ..Although a link between donor-specific antibodies against human leukocyte antigens type II (DSA II+) and transplant glomerulopathy has been clearly established, its role in cardiac allograft vasculopathy (CAV) is unclear...
  10. doi request reprint Changes in renal function after implantation of continuous-flow left ventricular assist devices
    Tal Hasin
    Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Am Coll Cardiol 59:26-36. 2012
    ..The aim of this study was to determine renal outcomes after left ventricular assist device (LVAD) implantation...
  11. ncbi request reprint Role of echocardiography in patients with intravascular hemolysis due to suspected continuous-flow LVAD thrombosis
    Nowell M Fine
    Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    JACC Cardiovasc Imaging 6:1129-40. 2013
    ..This study sought to characterize the echocardiographic findings of patients presenting with intravascular hemolysis (IVH) due to suspected continuous-flow left ventricular assist device (LVAD) pump thrombosis...
  12. doi request reprint Echocardiographic variables after left ventricular assist device implantation associated with adverse outcome
    Yan Topilsky
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Circ Cardiovasc Imaging 4:648-61. 2011
    ....
  13. ncbi request reprint Late allograft failure after heart transplantation: 2 unusual cases
    Barry A Boilson
    William Von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA
    J Heart Lung Transplant 27:1050-4. 2008
    ..We report 2 unusual cases of acute allograft dysfunction that highlight the importance of caution in adopting an empiric strategy of profound immunosuppression in the absence of objective data to support graft rejection...
  14. doi request reprint Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft
    Eugenia Raichlin
    Division of Cardiovascular Diseases and the William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN 55905, USA
    Transplantation 86:1395-400. 2008
    ..Left ventricular hypertrophy (LVH) and diastolic dysfunction occur after cardiac transplantation. We investigated sirolimus (SRL) as primary immunosuppression for the attenuation of LVH and diastolic dysfunction of the cardiac allograft...
  15. doi request reprint Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation
    Eugenia Raichlin
    William J von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 28:320-7. 2009
    ..Cardiac allograft vasculopathy (CAV) is primarily immune-mediated. We investigated the role of cellular rejection in CAV development...
  16. pmc TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation
    Jackson J Liang
    Department of aInternal Medicine bBiostatistics cMedicine, Division of Cardiovascular Diseases dDepartment of Molecular Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Mayo Clinic, Rochester, Minnesota, USA
    Pharmacogenet Genomics 23:658-65. 2013
    ..The objective of this study was therefore to determine the effect of TPMT genetic variation on AZA efficacy or prevention of rejection in HTX recipients treated with AZA...
  17. pmc Combined heart and liver transplant attenuates cardiac allograft vasculopathy compared with isolated heart transplantation
    Yan Topilsky
    Division of Cardiovascular Diseases, Tel Aviv Medical Center, Tel Aviv, Israel
    Transplantation 95:859-65. 2013
    ..We evaluated whether combined heart and liver transplant (H+LTx) can protect the heart graft from the development of cardiac allograft vasculopathy using coronary three-dimensional (3D) volumetric intravascular ultrasound (IVUS)...
  18. doi request reprint Readmissions after implantation of axial flow left ventricular assist device
    Tal Hasin
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 61:153-63. 2013
    ..The purpose of this study was to determine the occurrence and causes of readmissions after implantation of axial flow left ventricular assist device (LVAD)...
  19. doi request reprint Echocardiographic predictors of adverse outcomes after continuous left ventricular assist device implantation
    Yan Topilsky
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    JACC Cardiovasc Imaging 4:211-22. 2011
    ..The purpose of the study was to identify echocardiographic predictors of adverse outcome in patients implanted with continuous-flow left ventricular assist devices (LVAD)...
  20. doi request reprint B-type natriuretic peptide levels and continuous-flow left ventricular assist devices
    Basar Sareyyupoglu
    Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota 55205, USA
    ASAIO J 56:527-31. 2010
    ..The effective LVAD support seems to result in a marked reduction in BNP levels, and monitoring serial BNP levels may be helpful in managing patients supported on continuous LVAD...
  21. ncbi request reprint The role of medical management for acute intravascular hemolysis in patients supported on axial flow LVAD
    Tal Hasin
    From the Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota and Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota
    ASAIO J 60:9-14. 2014
    ..Medical treatment with intensification of anticoagulation can be effective in resolving the acute hemolytic event. However, a definitive long-term strategy should be planned because the recurrence rate is high. ..
  22. doi request reprint Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy
    Yan Topilsky
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55902, USA
    Circ Heart Fail 4:266-75. 2011
    ..The purpose of this study was therefore to analyze the outcome of LVAD therapy in these patients...
  23. doi request reprint Normal left ventricular mechanical function and synchrony values by speckle-tracking echocardiography in the transplanted heart with normal ejection fraction
    Haydar K Saleh
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 30:652-8. 2011
    ....
  24. ncbi request reprint The role of donor-specific antibodies in acute cardiac allograft dysfunction in the absence of cellular rejection
    Nowell M Fine
    1 Division of Cardiovascular Diseases, Department of Medicine, William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN 2 Division of Cardiovascular Surgery, Department of Surgery, William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN 3 Department of Laboratory Medicine and Pathology, William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN 4 Address correspondence to Naveen L Pereira, M D, Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55901
    Transplantation 98:229-38. 2014
    ..The role of donor-specific antibodies (DSAs) in AAD, with the increasing use of single antigen bead (SAB) assays that have improved the ability to detect DSA, remains unclear...
  25. ncbi request reprint Contemporary strategies in the diagnosis and management of heart failure
    Shannon M Dunlay
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN Electronic address
    Mayo Clin Proc 89:662-76. 2014
    ..This review provides a thorough update on contemporary strategies in the diagnosis and management of HF by stage (A to D) that have emerged during the past several years. ..
  26. ncbi request reprint An unusual presentation of post-transplant lymphoproliferative disorder mimicking vasculitis in heart transplantation
    David L Murray
    Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA
    J Heart Lung Transplant 27:1257-61. 2008
    ..Recognition of this novel PTLD pattern as a potential imitator of acute rejection in particular is important because reduction of immunosuppression (to treat PTLD) is antithetical to the usual therapy for rejection...
  27. pmc Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy
    Rahul Suresh
    Mayo Medical School, Mayo Clinic College of Medicine, Rochester, Minnesota
    J Am Soc Echocardiogr 27:440-7. 2014
    ..The investigators describe patients with histologically confirmed cardiac amyloidosis who had significant myocardial dysfunction (LVEF ≤ 40%) despite having normal IVS thickness...
  28. pmc A Functional Genetic Variant (N521D) in Natriuretic Peptide Receptor 3 Is Associated with Diastolic Dysfunction: The Prevalence of Asymptomatic Ventricular Dysfunction Study
    Naveen L Pereira
    Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 9:e85708. 2014
    ..To evaluate the impact of a functional genetic variant in the natriuretic peptide clearance receptor, NPR3, on circulating natriuretic peptides (NPs) and myocardial structure and function in the general community...
  29. doi request reprint Implantation of a HeartMate II left ventricular assist device via left thoracotomy
    Yang Hyun Cho
    Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA
    Ann Thorac Surg 94:1712-4. 2012
    ..We report a case of the use of left thoracotomy for the implantation of the HeartMate II axial-flow pump...
  30. doi request reprint Relationship between monoclonal gammopathy and cardiac amyloid type
    Joseph J Maleszewski
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Cardiovasc Pathol 22:189-94. 2013
    ..Validity of SPEP/UPEP/IFE and FLC assays in cardiac amyloid prediction was examined...
  31. doi request reprint Echocardiographic findings in stable outpatients with properly functioning HeartMate II left ventricular assist devices
    Yan Topilsky
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    J Am Soc Echocardiogr 24:157-69. 2011
    ..However, knowledge of normal values for transthoracic echocardiographic examination and measurements in these patients are lacking...
  32. ncbi request reprint Changes in cardiopulmonary exercise testing parameters following continuous flow left ventricular assist device implantation and heart transplantation
    Shannon M Dunlay
    Division of Cardiovascular Diseases in the Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota Division of Health Care Policy and Research in the Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota Electronic address
    J Card Fail 20:548-54. 2014
    ..However, little is known about how exercise capacity changes after LVAD and how changes compare with patients undergoing heart transplantation...
  33. pmc LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay
    Nisha Shankar
    University of Connecticut Health Center, Farmington, CT, USA
    Transplantation 96:324-30. 2013
    ..Whether sensitization occurs with continuous axial flow LVAD implant as assessed by single antigen bead (SAB) assay is unknown...
  34. doi request reprint Combined heart and liver transplantation: a single-center experience
    Eugenia Raichlin
    William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA
    Transplantation 88:219-25. 2009
    ..We analyze the long-term outcome of the patients undergoing CHLTx...
  35. ncbi request reprint Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients
    Jennifer L Peura
    Division of Cardiology, Department of Internal Medicine, Medical University of South Carolina, Gazes Cardiac Research Institute, Charleston 29425, USA
    J Heart Lung Transplant 24:1969-72. 2005
    ..Left ventricular mass decreased by 24% and left ventricular geometry returned toward normal at 6 months after conversion, without significant changes in blood pressure...